Replies to post #422258 on Amarin Corp Plc (AMRN)

[JRoon71]

Zip, beyond hi trigs and CVD, we need to actually have a positive outcome trial and get a new indication. We have yet to see that happen.

[DMC8]

https://classic.clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT04505098+OR+NCT03428477+OR+NCT04562467+OR+NCT02719327+OR+NCT04216251

[the_kube]

Lose the fish oil label and add a bunch more serious side effects and this drug could be a blockbuster.

[couldbebetter]

BP has to be the driving force for the drug to be accepted.
The only way that is likely to happen is if Alex Denner can
convince BP that AMRN's Vascepa (or a new version there of)
has many other indications beyond CVD. Given that Vascepa
makes most any medical outcome better, I would want to see
it used by Merck as an adjunct drug to their Keytruda. Why
nobody with stature (such as Dr. Bhatt) has not found a way
to do this is sickening. Vascepa remains the poster child for
the best example of a great drug laid to waste. Hopefully,
Alex Denner will change that.